The quality of life (QoL) of advanced stage lung adenocarcinoma patients receiving afatinib at Dr. Sardjito General Hospital, Yogyakarta
Abstract
Lung cancer has the highest mortality rate of all cancers. In its advanced stages, this disease is associated with poor survival rates and quality of life. The most common subtype of lung cancer is adenocarcinoma which is frequently associated with mutations in the epidermal growth factor receptor (EGFR), a protein crucial
for cell proliferation. The presence of EGFR mutations plays a key role in targeted therapy using tyrosine kinase inhibitors (TKIs). Afatinib is a second-generation TKI that offers several advantages over the first-generation. Afatinib is effective against complex and uncommon EGFR mutations, making it a commonly used
option for patients with lung adenocarcinoma. However, afatinib is also associated with a higher incidence of adverse drug reactions (ADRs) compared to other TKIs, which may impact therapeutic outcomes. This study aimed to assess the quality of life (QoL) of advanced lung adenocarcinoma patients with EGFR mutations and
the prevalence of ADRs associated with afatinib treatment at Dr. Sardjito General Hospital in Yogyakarta. The study employed an observational cross-sectional design. Prospective data collection was conducted for two months, from January to February 2025 at the Oncology Department following ethical approval. A total
of 15 patients were enrolled in this study. The most commonly identified ADRs were acne (45%), diarrhea (20%), paronychia (20%), and oral mucositis (15%). The mean QoL scores was 81.38 ± 10.01 for the functional scale, 15.93 ± 8.48 for the symptom scale, and 72.78 ± 19.53 for global health status.
References
Asmara OD, Tenda ED, Singh G, Pitoyo CW, Rumende CM, Rajabto W, et al. Lung cancer in Indonesia. J Thorac Oncol, 2023; 18(9):1134-45.
https://doi.org/10.1016/j.jtho.2023.06.010
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin, 2024; 74(1):12-49.
https://doi.org/10.3322/caac.21820
Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol, 2023; 24(11):1206-18.
https://doi.org/10.1016/S1470-2045(23)00444-8
Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol, 2023; 34(4):339-57.
https://doi.org/10.1016/j.annonc.2022.12.009
Edwards RL, Andan C, Lalla RV, Lacouture ME, O’Brien D, Sequist LV. Afatinib therapy: practical management of adverse events with an oral agent for non-small cell lung cancer treatment. Clin J Oncol Nursi, 2018; 22(5):542-48.
https://doi.org/10.1188/18.CJON.542-548
Witherspoon JN, Wagner L, Rademaker A, West DP, Rosenbaum SE, Lacouture ME. Correlation of patient characteristics and NCI-Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor-induced rash. J Clin Oncol, 2008; 26(15_suppl):9559.
https://doi.org/10.1200/jco.2008.26.15_suppl.9559
Perwitasari DA, Atthobari J, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, et al. Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia. Jpn J Clin Oncol, 2011; 41(4):519-29.
https://doi.org/10.1093/jjco/hyq243
Tamási L, Horváth K, Kiss Z, Bogos K, Ostoros G, Müller V, et al. Age and gender specific lung cancer incidence and mortality in Hungary: trends from 2011 through 2016. Pathol Oncol Res, 2021; 27:598862.
https://doi.org/10.3389/pore.2021.598862
Polanco D, Pinilla L, Gracia-Lavedan E, Mas A, Bertran S, Fierro G, et al. Prognostic value of symptoms at lung cancer diagnosis: a three-year observational study. J Thorac Dis, 2021; 13(3):1485-94.
https://doi.org/10.21037/jtd-20-3075
Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol, 2015; 3(1):217-21.
https://doi.org/10.3892/mco.2014.410
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget, 2016; 7(48):78985-93.
https://doi.org/10.18632/oncotarget.12587
O’Leary C, Gasper H, Sahin KB, Tang M, Kulasinghe A, Adams MN, et al. Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals (Basel), 2020; 13(10):273.
https://doi.org/10.3390/ph13100273
Banno E, Togashi Y, Kobayashi Y, Hayashi H, Mitsudomi T, Nishio K. Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion. Anticancer Res, 2015; 35(4):2005-8.
Yang JCH, Sequist LV, Zhou C, Schuler M, Geater SL, Mok T, et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol, 2016; 27(11):2103-10.
https://doi.org/10.1093/annonc/mdw322
Lacouture ME, Schadendorf D, Chu CY, Uttenreuther-Fischer M, Stammberger U, O’Brien D, et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther, 2013; 13(6):721-8.
https://doi.org/10.1586/era.13.30
Lavdaniti M, Chavela A, Chatzinikolaou A, Chatzi I, Stalika E, Palitzika D, et al. Adverse effects of chemotherapy influence the patients’ quality of life: Analysis of implicated factors. Ann Oncol, 2019; 30(Suppl5):v842.
https://doi.org/10.1093/annonc/mdz276.025
Pompili C, Omar S, Ilyas MH, Velikova G, Dalmia S, Valuckiene L, et al. Patient-reported physical function is associated with survival after lung resection for non-small cell lung cancer. Ann Thorac Surg, 2023; 116(3):563-9.
https://doi.org/10.1016/j.athoracsur.2022.09.047
Shorter E, Engman V, Lanner JT. Cancer-associated muscle weakness - from triggers to molecular mechanisms. Mol Aspects Med, 2024; 97:101260.
https://doi.org/10.1016/j.mam.2024.101260
Smith HR. Depression in cancer patients: pathogenesis, implications and treatment (Review). Oncol Lett, 2015; 9(4):1509-14.
https://doi.org/10.3892/ol.2015.2944
Muthanna FMS, Hassan BAR, Karuppannan M, Ibrahim HK, Mohammed AH, Abdulrahman E. Prevalence and Impact of Fatigue on Quality of Life (QOL) of cancer patients undergoing chemotherapy: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 2023; 24(3):769-81.
https://doi.org/10.31557/APJCP.2023.24.3.769
Thong MSY, van Noorden CJF, Steindorf K, Arndt V. Cancer-related fatigue: causes and current treatment options. Curr Treat Options Oncol, 2020; 21(2):17.
https://doi.org/10.1007/s11864-020-0707-5
Ma Y, He B, Jiang M, Yang Y, Wang C, Huang C, et al. Prevalence and risk factors of cancer-related fatigue: A systematic review and meta-analysis. Int J Nurs Stud, 2020; 111:103707.
https://doi.org/10.1016/j.ijnurstu.2020.103707
Riccetti N, Blettner M, Taylor K, Wehler B, Gohrbandt B, Nestle U, et al. Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS. J Cancer Res Clin Oncol, 2022; 148(8):1943-53.
https://doi.org/10.1007/s00432-022-03975-6
Simmons CPL, MacLeod N, Laird BJA. Clinical management of pain in advanced lung cancer. Clin Med Insights Oncol, 2012; 6:331-46.
https://doi.org/10.4137/CMO.S8360
Ariantika A, Lubis R, Asfriyati A, Ashar T, Nurmaini N, Soeroso NN, et al. Assessment of quality of life in advanced-stage lung cancer patients using EORTC QLQ-C30 Questionnaire. J Resp, 2024; 10(3):228-35.
https://doi.org/10.20473/jr.v10-I.3.2024.228-235
Costa MFFD, Bilobran MA, de Oliveira LC, Muniz AHR, Chelles PA, Sampaio SGDSM. Correlation between cancer pain and quality of life in patients with advanced cancer admitted to a palliative care unit. Am J Hosp Palliat Care, 2024; 41(8):882-8.
https://doi.org/10.1177/10499091231195318
Grande GE, Farquhar MC, Barclay SIG, Todd CJ. Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients. Palliat Support Care, 2009; 7(3):289-97.
https://doi.org/ 10.1017/S1478951509990216
Rosentreter J, Alt J, Fried M, Chakupurakal G, Stratmann J, Krämer I. Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors. J Oncol Pharm Pract, 2021; 27(5):1147-58.
https://doi.org/10.1177/1078155220946381.
Okajima M, Miura S, Watanabe S, Tanaka H, Ito K, Ishida T, et al. A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401). Transl Lung Cancer Res, 2021; 10(1):252-60.
